[1]王玉婷,黄钢,蒋瑾,等.18F-FDG PET用于肿瘤治疗疗效评价的meta分析进展[J].国际放射医学核医学杂志,2012,36(6):334-338.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
　WANG Yu-ting,HUANG Gang,JIANG Jin,et al.Tumor response monitoring by 18F-FDG PET: updated review of meta-analyses[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):334-338.[doi:10.3760/cma.j.issn.1673-4114.2012.06.004]
点击复制

18F-FDG PET用于肿瘤治疗疗效评价的meta分析进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
36
期数:
2012年第6期
页码:
334-338
栏目:
PET-CT临床应用及新进展(重点专题)
出版日期:
1900-01-01

文章信息/Info

Title:
Tumor response monitoring by 18F-FDG PET: updated review of meta-analyses
作者:
王玉婷1;  黄钢2;  蒋瑾1;  陈加源1
1. 四川省医学科学院四川省人民医院放射科, 成都 610072;
2. 上海交通大学医学院, 上海 200025
Author(s):
WANG Yu-ting1;  HUANG Gang2;  JIANG Jin1;  CHEN Jia-yuan1
Department of Radiology, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, Chengdu 610072, China
关键词:
肿瘤; 治疗结果; Meta分析; 氟脱氧葡萄糖F18; 正电子发射断层显像术
Keywords:
Neoplasms; Treatment outcome; Meta-analysis; Fluorodeoxyglucose F18; Positron emission tomography
DOI:
10.3760/cma.j.issn.1673-4114.2012.06.004
摘要:
目前,大部分抗肿瘤治疗只在某些患者亚组中有效,对肿瘤治疗疗效的个体化监测的需求日益突出。传统解剖显像用于肿瘤治疗疗效的评价尚存在一些缺陷,而18F-FDG PET在肿瘤中的临床应用及其meta分析等统计学证据不断增多,该文将对其监测多种肿瘤的治疗疗效的应用情况进行综合性的回顾。基于PET能早期显示肿瘤的代谢特征,比传统解剖显像具有独特的优势,多项meta分析结果显示其用于疗效评价的准确率普遍较高。在某些肿瘤如淋巴瘤中,PET因其较高的灵敏度和特异度,已写入新的国际诊疗指南;而在其他多种肿瘤如非小细胞肺癌、乳腺癌、食管癌、胃食管交界处腺癌、直肠癌、胃肠道间质瘤等中,PET仍存在缺乏临床标准方案、各研究结果间异质性大等问题。此外,PET检查结果中还存在一定的假阳性和假阴性,在临床应用中需分析原因,提高警惕。因此,今后仍需要更多大样本的前瞻性、随机化实验来充分验证PET在肿瘤治疗疗效评价中的地位。
Abstract:
Most anticancer drugs are effective only in subgroups of patients, which makes the individualization of tumor response monitoring quite in need. Since the current anatomic imaging has certain limitations for this utility, and the clinical evidence of 18F-FDG PET from meta-analysis is increasing, this study gives a comprehensive review of the performance of PET in monitoring response of a variety of tumors. Given the early metabolic characterization of tumors by PET, this technology exhibited special advantages to traditional imaging modalities and generally yielded high accuracies in tumor response assessment in many meta-analyses. In certain type of tumors as malignant lymphoma, PET has recently been placed to a central role in defining tumor response in international criteria. In other tumors as non-small cell lung cancer, breast cancer, esophageal cancer, adenocarcinomas of the esophagogastric junction, rectal cancer and gastrointestinal stromal tumor, questions remain due to lack of standard regimen of PET and heterogeneity between individual study results. Besides, certain numbers of false positive and false negative results of PET still call for caution in clinical scenarios. More prospective and large sampled random trials are warranted to fully validate and position PET in tumor management.

参考文献/References:

[1] Strauss GM,Herndon JE 2nd,Maddaus MA,et al.Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer:CALGB 9633 with the Cancer and Leukemia Group B,Radiation Therapy Oncology Group,and North Central Cancer Treatment Group study groups.J Clin Oncol,2008,26(31):5043-5051.
[2] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1).Eur J Cancer,2009,45(2):228-247.
[3] Weber WA,Assessing tumor response to therapy.J Nucl Med,2009,50 Suppl 1:1S-10.
[4] Hillner BE,Siegel BA,Liu D,et al.Impact of positron emission tomography/computed tomography and positron emission tomography(PET) alone on expected management of patients with cancer:initial results from the National Oncologic PET Registry.J Clin Oncol,2008,26(13):2155-2161.
[5] Therasse P,Eisenhauer EA,Verweij J.RECIST revisited:a review of validation studies on tumour assessment.Eur J Cancer,2006,42(8):1031-1039.
[6] Wahl RL,Jacene H,Kasamon Y,et al.From RECIST to PERCIST:evolving considerations for PET response criteria in solid tumors.J Nucl Med,2009,50 Suppl 1:122S-150.
[7] Hutchings M,Barrington SF.PET/CT for therapy response assessment in lymphoma.J Nucl Med,2009,50 Suppl 1:21S-30.
[8] Zinzani PL,Gandolfi L,Broccoli A,et al.Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.Cancer,2011,117(5):1010-1018.
[9] Cheson BD,Pfistner B,Juweid ME,et al.Revised response criteria for malignant lymphoma.J Clin Oncol,2007,25(5):579-586.
[10] Ramos-Font C,Rebollo Aguirre AC,Villegas Portero R,et al,18F-fluorodeoxyglucose positron emission tomography in the evaluation of therapy response assessment in lymphomas.Systematic literature review and meta-analysis.Rev Esp Med Nucl,2009,28(2):48-55.
[11] Zijlstra JM,Lindauer-van der Werf G,Hoekstra OS,et al.18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma:a systematic review.Haematologica,2006,91(4):522-529.
[12] Terasawa T,Nihashi T,Hotta T,et al.18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive Non-Hodgkin’s lymphoma:a systematic review.J Nucl Med,2008,49(1):13-21.
[13] Terasawa T,Dahabreh IJ,Nihashi T.Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma:a systematic review and meta-analysis.Oncologist,2010,15(7):750-759.
[14] Rebollo-Aguirre AC,Ramos-Font C,Villegas Portero R,et al.Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature,J Surg Oncol,2010,101(6):486-494.
[15] Avril N,Sassen S,Roylance R.Response to therapy in breast cancer.J Nucl Med,2009,50 Suppl 1:55S-63.
[16] Wang Y,Zhang C,Liu J,et al.Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis.Breast Cancer Res Treat,2012,131(2):357-369.
[17] Cheng X,Li Y,Liu B,et al.18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer:a meta-analysis.Acta Radiol,2012,53(6):615-627.
[18] Graham AJ,Shrive FM,Ghali WA,et al.Defining the optimal treatment of locally advanced esophageal cancer:a systematic review and decision analysis.Ann Thorac Surg,2007,83(4):1257-1264.
[19] Rebollo Aguirre AC,Ramos-Font C,Villegas Portero R,et al.18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer:systematic review of the literature.Ann Surg,2009,250(2):247-254.
[20] Westerterp M,van Westreenen HL,Reitsma JB,et al.Esophageal cancer:CT,endoscopic US,and FDG PET for assessment of response to neoadjuvant therapy-systematic review.Radiology,2005,236(3):841-851.
[21] Yanagawa M,Tatsumi M,Miyata H,et al.Evaluation of response to neoadjuvant chemotherapy for esophageal cancer:PET response criteria in solid tumors versus response evaluation criteria in solid tumors.J Nucl Med,2012,53(6):872-880.
[22] Suttie SA,Welch AE,Park KG.Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma.Eur J Surg Oncol,2009,35(10):1019-1029.
[23] Neuman HB,Elkin EB,Guillem JG,et al.Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy:a decision analysis,Dis Colon Rectum,2009,52(5):863-871.
[24] Zhang C,Tong J,Sun X,et al.18F-FDG-PET evaluation of treatment response to neoadjuvant therapy in patients with locally advanced rectal cancer:a meta-analysis.Int J Cancer,2012,131(11):2604-2611.
[25] Young H,Baum R,Cremerius U,et al.Measurement of clinical andsubclinical tumour response using[18F]-fluorodeoxyglucose and positron emission tomography:review and 1999 EORTC recommendations.European Organization for Research and Treatment of Cancer(EORTC) PET Study Group.Eur J Cancer,1999,35(13):1773-1782.
[26] Treglia G,Mirk P,Stefanelli A,et al.18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors:a systematic review.Clin Imaging,2012,36(3):167-175.
[27] Dose-Schwarz J,Tiling R,Avril-Sassen S,et al.Assessment of residual tumour by FDG-PET:conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.Br J Cancer,2010,102(1):35-41.
[28] Park JS,Moon W K,Lyou CY,et al.The assessment of breast cancer response to neoadjuvant chemotherapy:comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.Acta Radiol,2011,52(1):21-28.

相似文献/References:

[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
　He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
　Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
　Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
　Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[5]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
　zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[6]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
　Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[7]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
　Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[8]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
　Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[9]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[10]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
　Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]

备注/Memo

备注/Memo:
收稿日期:2012-08-17。
通讯作者:陈加源(Email:13688451707@126.com)
更新日期/Last Update: 1900-01-01